EVIDENCE LIBRARY
Dutch Prescribing-Data Interviews Identified Why Benzodiazepine Counts Need Indication and Dispensing Context
A qualitative study found that stakeholders needed linked clinical, pharmacy, and claims data. It did not validate a prescribing count as a complete measure of appropriateness.
A qualitative study found that stakeholders needed linked clinical, pharmacy, and claims data. It did not validate a prescribing count as a complete measure of appropriateness.
What the interviews examined
Twenty-eight informants represented clinical, organizational, research, technical, and policy perspectives. Benzodiazepines, opioids, and antibiotics served as tracer prescription types.
Themes included measuring relevant outcomes, linking data, improving quality, sharing information, and fitting analysis to its intended use. Clinical records, pharmacy records, and insurer claims each offered different information.
A count answers a limited question
A prescription does not necessarily establish dispensing, ingestion, indication, or long-term continuous exposure. Likewise, a population indicator designed for policy may not resolve an individual patient’s treatment needs.
This was an exploratory interview study in the Dutch setting, not a trial demonstrating that a particular indicator reduced harm. The findings support reconstructing a longitudinal medication history from complementary records. They cannot establish that a flagged benzodiazepine prescription was inappropriate or that an unflagged pattern was harmless without the underlying clinical context.
Source paper
Original analysis of the supplied journal article, identified as PMC9310167.